The efficacy of 9-cis-retinoic acid (aliretinoin) as a chemopreventive agent for cervical dysplasia: results of a randomized double-blind clinical trial
- PMID: 12582020
The efficacy of 9-cis-retinoic acid (aliretinoin) as a chemopreventive agent for cervical dysplasia: results of a randomized double-blind clinical trial
Abstract
9-Cis-retinoic acid (aliretinoin) is a pan-retinoid receptor agonist and has been demonstrated in preclinical models to have potent chemoprevention effects. The purpose of this study was to determine the utility of using aliretinoin as a chemoprevention agent in cervical dysplasia. Patients with histological evidence of cervical intraepithelial neoplasia (CIN) 2/3 were randomized in a double-blind manner to receive high-dose aliretinoin (50 mg), low-dose of aliretinoin (25 mg), or placebo daily for 12 weeks. Compliance and side effects were monitored at various time points during therapy. At the completion of therapy, all of the patients underwent a loop procedure. Histology of pretreatment biopsies was compared with that of loop specimens. One-hundred and fourteen patients with CIN 2/3 were enrolled in the study. In the 112 patients evaluable for toxicity, headache was the most common clinical side effect and was experienced more frequently (74%) in the high-dose aliretinoin group. Eight patients withdrew from the study before completion of study medication because of unacceptable side effects. In the 104 patients evaluable for efficacy, there was no statistical difference in the rate of regression among the placebo (32%), the low-dose aliretinoin (32%), and the high-dose aliretinoin (36%) groups. (P = not significant; power 0.06). Aliretinoin at these dosages and this schedule does not appear to result in significant regression rates in CIN 2/3 patients when compared with placebo. Headache is encountered frequently and may thwart efforts to increase the dose or duration of aliretinoin in future cervical cancer chemoprevention studies. The rate of histological regression in biopsied CIN 2/3 patients is high even over a short time interval, and emphasizes the importance of having a placebo arm and an adequate sample size in cervical dysplasia chemoprevention studies.
Similar articles
-
Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial.J Natl Cancer Inst. 1994 Apr 6;86(7):539-43. doi: 10.1093/jnci/86.7.539. J Natl Cancer Inst. 1994. PMID: 8133537 Clinical Trial.
-
Low-dose topical delivery of all-trans retinoic acid for cervical intraepithelial neoplasia II and III.Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2148-52. Cancer Epidemiol Biomarkers Prev. 2004. PMID: 15598773 Clinical Trial.
-
Epidermal growth factor receptor expression in cervical intraepithelial neoplasia and its modulation during an alpha-difluoromethylornithine chemoprevention trial.Clin Cancer Res. 1998 Jun;4(6):1383-91. Clin Cancer Res. 1998. PMID: 9626454
-
Retinoids for preventing the progression of cervical intra-epithelial neoplasia.Cochrane Database Syst Rev. 2013 Jun 6;2013(6):CD003296. doi: 10.1002/14651858.CD003296.pub3. Cochrane Database Syst Rev. 2013. PMID: 23740788 Free PMC article. Review.
-
Retinoids for preventing the progression of cervical intra-epithelial neoplasia.Cochrane Database Syst Rev. 2007 Oct 17;(4):CD003296. doi: 10.1002/14651858.CD003296.pub2. Cochrane Database Syst Rev. 2007. Update in: Cochrane Database Syst Rev. 2013 Jun 06;(6):CD003296. doi: 10.1002/14651858.CD003296.pub3. PMID: 17943787 Updated. Review.
Cited by
-
Retinoids: Molecular Aspects and Treatment in Premalignant Lesions and Cervical Cancer.Cancer Control. 2024 Jan-Dec;31:10732748241279514. doi: 10.1177/10732748241279514. Cancer Control. 2024. PMID: 39163121 Free PMC article. Review.
-
Androgen promotes squamous differentiation of atypical cells in cervical intraepithelial neoplasia via an ELF3-dependent pathway.Cancer Med. 2023 May;12(9):10816-10828. doi: 10.1002/cam4.5824. Epub 2023 Mar 23. Cancer Med. 2023. PMID: 36951594 Free PMC article.
-
Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis.BMJ. 2018 Feb 27;360:k499. doi: 10.1136/bmj.k499. BMJ. 2018. PMID: 29487049 Free PMC article. Review.
-
Non-steroidal anti-inflammatory agents to induce regression and prevent the progression of cervical intraepithelial neoplasia.Cochrane Database Syst Rev. 2018 Feb 12;2(2):CD004121. doi: 10.1002/14651858.CD004121.pub4. Cochrane Database Syst Rev. 2018. PMID: 29431861 Free PMC article. Review.
-
TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC trial): study protocol for a randomized controlled trial.BMC Cancer. 2016 Feb 20;16:132. doi: 10.1186/s12885-016-2187-3. BMC Cancer. 2016. PMID: 26897518 Free PMC article. Clinical Trial.